# Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

> **NCT06207370** · PHASE2 · RECRUITING · sponsor: **60 Degrees Pharmaceuticals LLC** · enrollment: 33 (estimated)

## Conditions studied

- Babesiosis

## Interventions

- **DRUG:** Tafenoquine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06207370
- **Lead sponsor:** 60 Degrees Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06207370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06207370, "Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06207370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*